Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Identification of immunopeptides (pHLA) as candidate therapeutic targets in chondrosarcoma.

Journal of bone oncology·2026

Same author

Early Metabolic Risk in Childhood Brain Cancer Survivors with Childhood-Onset Growth Hormone Deficiency.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2026

Same author

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026

Same author

Automatic lesion segmentation in ⁶⁸Ga-PSMA PET/CT and ¹⁷⁷Lu-PSMA SPECT/CT: added value of PET-guided SPECT in a bicentric study.

EJNMMI research·2026

Same author

Muscle contribution in lipid nanoparticle mediated mRNA vaccine delivery and efficacy.

Journal of controlled release : official journal of the Controlled Release Society·2026

Same author

Fully GMP-complient radiosynthesis of [<sup>161</sup>Tb]Tb-PSMA-1 using the miniAiO synthesizer for clinical translation.

EJNMMI radiopharmacy and chemistry·2026

Search research articles

Related Experiment Video

Updated: May 28, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Radioligand Therapy (RLT) in France.

Anne-Laure Giraudet¹, David Kryza¹, Lavinia Vija²

¹Léon Bérard Cancer Center, Lyon, France.

European Urology Focus

|May 26, 2026

Summary

France established a national radioligand therapy (RLT) network to meet rising demand for prostate cancer treatment. This network supports nuclear medicine departments, increasing patient access to innovative RLT.

Keywords:

Nuclear medicine Prostate cancer Radioligand therapy Radionuclide therapy

More Related Videos

Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models

Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models

Published on: July 7, 2016

Fluorescence-Activated Cell Sorting-Radioligand Treated Tissue (FACS-RTT) to Determine the Cellular Origin of Radioactive Signal

Fluorescence-Activated Cell Sorting-Radioligand Treated Tissue (FACS-RTT) to Determine the Cellular Origin of Radioactive Signal

Published on: September 10, 2021

Related Experiment Videos

Last Updated: May 28, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models

Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models

Published on: July 7, 2016

Fluorescence-Activated Cell Sorting-Radioligand Treated Tissue (FACS-RTT) to Determine the Cellular Origin of Radioactive Signal

Fluorescence-Activated Cell Sorting-Radioligand Treated Tissue (FACS-RTT) to Determine the Cellular Origin of Radioactive Signal

Published on: September 10, 2021

Area of Science:

Oncology
Nuclear Medicine
Health Services Research

Background:

The VISION trial's 2021 success highlighted the potential of radioligand therapy (RLT).
There is a growing demand for RLT, particularly in prostate cancer treatment.
Existing healthcare structures needed adaptation to meet this demand.

Purpose of the Study:

To outline France's organizational strategy for meeting the increased demand for RLT.
To describe the establishment and function of a national RLT network.
To assess how the network addresses supply-demand gaps and facilitates RLT implementation.

Main Methods:

Analysis of France's healthcare reorganization following the VISION trial.
Description of the national RLT network's structure and stakeholders.
Identification of supply-demand dynamics within nuclear medicine departments.

Main Results:

A national RLT network has been progressively established in France.
This network serves as a central coordinating body for various stakeholders.
The network aims to identify and bridge gaps between RLT supply and demand.

Conclusions:

France has reorganized to address the growing need for radioligand therapy.
The national RLT network is crucial for supporting nuclear medicine departments.
This initiative expands patient access to RLT for prostate cancer and other malignancies.